OPKO Health, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
OPKO Health, Inc. (OPK) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-26
- OPKO Health, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- OPKO Health, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $23.40M.
- OPKO Health, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- OPKO Health, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $0.00.
- OPKO Health, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00.
- OPKO Health, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- OPKO Health, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $29.36M.
- OPKO Health, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | ||||
| 2023-12-31 | $23.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $29.36M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $5.97M 10-Q · filed 2024-11-07 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 10-K · filed 2025-03-03 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-06 | ||||
| 2021-12-31 | $6.49M 10-K · filed 2024-03-01 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | $0.00 10-K · filed 2023-02-27 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $0.00 derived: sum of 2 quarters · filed 2020-10-29 | $0.00 10-Q · filed 2020-10-29 | -$35.83M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $0.00 10-Q · filed 2020-07-31 | -$35.83M derived: sum of 3 quarters · filed 2022-03-01 | -$29.64M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-06 | -$35.83M derived: sum of 2 quarters · filed 2022-03-01 | -$29.64M derived: sum of 3 quarters · filed 2022-03-01 | -$33.28M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2019-12-31 | -$35.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$29.64M derived: sum of 2 quarters · filed 2022-03-01 | -$33.28M derived: sum of 3 quarters · filed 2022-03-01 | $0.00 10-K · filed 2022-03-01 | $39.38M 10-K · filed 2020-03-02 |
| 2019-09-30 | $6.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $2.55M derived: sum of 2 quarters · filed 2020-10-29 | $35.83M 10-Q · filed 2020-10-29 | ||
| 2019-06-30 | -$3.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $29.64M 10-Q · filed 2020-07-31 | |||
| 2019-03-31 | $33.28M 10-Q · filed 2020-05-06 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-18 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |